Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Objective

The study aims to compare the efficacies of the immunosuppressants most commonly prescribed for patients with neuromyelitis optica spectrum disorder (NMOSD). The predictors, which might be associated with relapse and disability in NMOSD, were also analyzed.

Methods

This retrospective study included NMOSD patients treated with azathioprine (AZA), mycophenolate mofetil (MMF), and rituximab (RTX). The annual relapse rate (ARR) and the incidence rates of adverse events were compared. Cox proportional-hazards model calculated the potential predictors of NMOSD relapse and disability.

Results

A total of 83 patients were included. The median treatment time of AZA group (n = 34), MMF group (n = 20), and RTX group (n = 29) were 19.5, 15.5, and 12 months, respectively. ARR of the three groups reduced significantly after treatment. In the three groups, 55.9%, 50%, and 79.3% of patients, respectively, were free from relapse. However, the difference among the three groups was of no statistical significance, possibly due to the small sample size. During the treatment, 32.4%, 15%, and 24.1% of patients experienced adverse events in the AZA group, MMF group, and RTX group, respectively. Additionally, the multivariate Cox analyses indicated that history of a severe attack and disease duration were associated with the risk of relapse after immunotherapy. Late-onset (≥ 50 years old) NMOSD patients were probably more susceptible to motor disability, and those with optic neuritis at onset were more likely to develop visual disability.

Conclusions

AZA, MMF, and low-dose RTX were all effective in reducing the relapse rate in NMOSD. The age at onset, disease duration, history of severe attacks, and primary syndromes might be significant prognostic predictors in NMOSD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189

    Article  Google Scholar 

  2. Franciotta D, Gastaldi M, Sala A et al (2017) Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci 38:231–236

    Article  Google Scholar 

  3. Rezaeimanesh N, Sahraian MA, Moghadasi AN et al (2020) Epidemiology of neuromyelitis optica spectrum disorder in Tehran, Iran: the prevalence, baseline characteristics, and clinical aspects. Neurol Sci 41(9):2647–2648

    Article  Google Scholar 

  4. Mori M, Kuwabara S, Paul F (2018) Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 89(6):555–556

    Article  Google Scholar 

  5. Bruscolini A, La Cava M, Mallone F et al (2019) Controversies in the management of neuromyelitis optica spectrum disorder. Expert Rev Neurother 19(11):1127–1133

    Article  CAS  Google Scholar 

  6. Zekeridou A, Lennon VA (2015) Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2(4):e110

    Article  Google Scholar 

  7. Graber DJ, Levy M, Kerr D, Wade WF (2008) Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 5:22

    Article  Google Scholar 

  8. Fujihara K, Cook LJ (2020) Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. Curr Opin Neurol 33(3):300–308

    Article  CAS  Google Scholar 

  9. Marchionatti A, Woodhall M, Waters PJ et al (2021) Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice. Neurol Sci 42(1):73–80

    Article  Google Scholar 

  10. Maniscalco GT, Allegorico L, Alfieri G et al (2021) Anti-MOG-associated demyelinating disorders: two sides of the same coin. Neurol Sci 42(4):1531–1534

    Article  Google Scholar 

  11. ZhangBao J, Huang W, Zhou L et al (2021) Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: a comparative study in Chinese Han patients. Eur J Neurol 28(4):1308–1315

    Article  Google Scholar 

  12. Mealy MA, Wingerchuk DM, Greenberg BM et al (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69(9):1176–1180

    Article  Google Scholar 

  13. Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8):1019–1032

    Article  CAS  Google Scholar 

  14. Neuroimmunology branch of Chinese Society for Immunology (2016) Diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) in China. Chin J Neuroimmunol & Neurol 23(3):155–166

    Google Scholar 

  15. Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310–1323

    Article  Google Scholar 

  16. Shi Z, Du Q, Chen H et al (2019) Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol. 2020;267(4):913–924

  17. Mealy MA, Mossburg SE, Kim SH et al (2019) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 28:64–68

    Article  Google Scholar 

  18. Nikoo Z, Badihian S, Shaygannejad V et al (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264(9):2003–2009

    Article  CAS  Google Scholar 

  19. Qiu W, Kermode AG, Li R et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178–1182

    Article  CAS  Google Scholar 

  20. Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659–666

    Article  CAS  Google Scholar 

  21. Bichuetti DB, Perin M, Souza NA et al (2019) Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler 25(8):1150–1161

    Article  CAS  Google Scholar 

  22. Espiritu AI, Pasco P (2019) Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 33:22–32

    Article  Google Scholar 

  23. Jiao Y, Cui L, Zhang W et al (2018) Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurol 18(1):47

    Article  Google Scholar 

  24. Huang Q, Wang J, Zhou Y et al (2018) Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol 9:2066

    Article  Google Scholar 

  25. Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 19(1):36

    Article  Google Scholar 

  26. Yang Y, Wang CJ, Wang BJ et al (2018) Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 385:192–197

    Article  CAS  Google Scholar 

  27. Yu H, Chen XJ, Yu X et al (2019) Efficacy and safety of reduced dosage of rituximab in Chinese patients with NMOSD. Chin J Clin Neurosci 27(03):309–312

    Google Scholar 

  28. Poupart J, Giovannelli J, Deschamps R et al (2020) Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645–e1656.

  29. Huang W, Wang L, Zhang B et al (2019) Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord 35:246–252

    Article  Google Scholar 

  30. Chen H, Zhang Y, Shi Z et al (2016) The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol 39(2):81–87

    Article  CAS  Google Scholar 

  31. Kunchok A, Malpas C, Nytrova P et al (2019) Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 38:101868

    Article  Google Scholar 

  32. Stellmann JP, Krumbholz M, Friede T et al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 88(8):639–647

    Article  Google Scholar 

  33. Kim SH, Mealy MA, Levy M et al (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91(22):e2089–e2099

    Article  Google Scholar 

  34. Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135(Pt 6):1834–1849

    Article  Google Scholar 

  35. Sepulveda M, Delgado-García G, Blanco Y et al (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e607.

Download references

Acknowledgements

Financial support was obtained from the medical practical technology tracking project of hebei province(GZ2020010).

Author information

Authors and Affiliations

  1. Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China

    Lu Zhang, Jingyuan Tian, Xiuyu Dong, Zhen Jia, Yafei Sun, Li Guo, Guojun Tan & Bin Li

  2. Key Laboratory of Hebei Neurology, Shijiazhuang, 050000, Hebei, China

    Lu Zhang, Jingyuan Tian, Xiuyu Dong, Zhen Jia, Yafei Sun, Li Guo, Guojun Tan & Bin Li

Authors
  1. Lu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingyuan Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiuyu Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhen Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yafei Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guojun Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guojun Tan or Bin Li.

Ethics declarations

Ethical approval

None.

Conflict of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Tian, J., Dong, X. et al. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors. Neurol Sci 43, 2651–2658 (2022). https://doi.org/10.1007/s10072-021-05609-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05609-0

Keywords

Search

Navigation